What Is the Chance of a Normal Pregnancy in a Woman Whose Fetus Has Been Exposed to Isotretinoin? | Congenital Defects | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.177.17. Please contact the publisher to request reinstatement.
1.
Lindstrom  J Isotretinoin: background and regulatory history.  FDA Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee Meeting February 26–27, 2004 Gaithersburg, MDhttp://www.fda.gov/ohrms/dockets/ac/04/slides/4017s1.htmAccessed March 1, 2007
2.
Abroms  LMaibach  ELyon-Daniel  KFeldman  SR What is the best approach to reducing birth defects associated with isotretinoin?  PLoS Med 2006;3 (11) e483PubMedGoogle ScholarCrossref
3.
Dai  WSLaBraico  JMStern  RS Epidemiology of isotretinoin exposure during pregnancy.  J Am Acad Dermatol 1992;26 (4) 599- 606PubMedGoogle ScholarCrossref
4.
Lammer  EJChen  DTHoar  RM  et al.  Retinoic acid embryopathy.  N Engl J Med 1985;313 (14) 837- 841PubMedGoogle ScholarCrossref
5.
Mitchell  AAVan Bennekom  CMLouik  C A pregnancy-prevention program in women of childbearing age receiving Isotretinoin.  N Engl J Med 1995;333 (2) 101- 106PubMedGoogle ScholarCrossref
6.
Bérard  AAzoulay  LKoren  GBlais  LPerreault  SOraichi  D Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective.  Br J Clin Pharmacol 2007;63 (2) 196- 205PubMedGoogle ScholarCrossref
7.
Lynberg  MCKhoury  MJLammer  EJWaller  KOCordero  JFErickson  JD Sensitivity, specificity, and positive predictive value of multiple malformations in isotretinoin embryopathy surveillance.  Teratology 1990;42 (5) 513- 519PubMedGoogle ScholarCrossref
8.
Stern  RSRosa  FBaum  C Isotretinoin and pregnancy.  J Am Acad Dermatol 1984;10 (5, pt 1) 851- 854PubMedGoogle ScholarCrossref
9.
Adams  JLammer  EJ Neurobehavioral teratology of isotretinoin.  Reprod Toxicol 1993;7 (2) 175- 177PubMedGoogle ScholarCrossref
10.
National Teratology Information Service, Exposure to Isotretinoin During Pregnancy.  Newcastle upon Tyne, England: National Teratology Information Service, Regional Drug and Therapeutics Centre 2001;Google Scholar
11.
Food and Drug Administration, iPLEDGE update. 2006;http://www.fda.gov/cder/drug/infopage/accutane/iPLEDGEupdate200603.htmAccessed May 2, 2007
12.
Goldsmith  LABolognia  JLCallen  JP  et al.  American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations.  J Am Acad Dermatol 2004;50 (6) 900- 906published correction for a dosage error appears in J Am Acad Dermatol 2004;51 (3) 348PubMedGoogle ScholarCrossref
13.
Rothman  KFPochi  PE Use of oral and topical agents for acne in pregnancy.  J Am Acad Dermatol 1988;19 (3) 431- 442PubMedGoogle ScholarCrossref
Evidence-Based Dermatology: Critically Appraised Topic
September 2007

What Is the Chance of a Normal Pregnancy in a Woman Whose Fetus Has Been Exposed to Isotretinoin?

Arch Dermatol. 2007;143(9):1187-1188. doi:10.1001/archderm.143.9.1187

Recently, one of our patients who was taking isotretinoin became pregnant. This occurred despite appropriate counseling, a negative pregnancy test result before commencing treatment, and use of the combined oral contraceptive pill Microgynon 30 (Schering Health Care, West Sussex, England) (levonorgestrel, 150 μg, ethinylestradiol, 30 μg). The patient did not want to terminate her pregnancy. The aim of this Critically Appraised Topic is to explore the literature to determine the chance of delivering a healthy child after fetal exposure to isotretinoin; the types of fetal malformations associated with it; and what monitoring should be performed.

Since introduction of the drug in 1982, over 2000 pregnancies in the United States have been affected by fetal exposure to isotretinoin,1 most resulting in spontaneous or elective abortions.2-6

×